Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
Combivent Respimat Transition Almost Complete Transition of Combivent Respimat is nearly complete as Boehringer Ingelheim plans to cease distribution of Combivent MDI in May. Boehringer Ingelheim ...
U.S. regulators have stamped an approval on a new inhaler that reduces the required inhalations per dose for Boehringer Ingelheim's treatment for chronic obstructive pulmonary disease (COPD), the ...
Statement: “Big drug companies charge as little as $7 for an inhaler overseas and nearly $500 for the exact same one here in the US.” Are Americans paying nearly $500 for an inhaler that would cost ...
The U.S. Food and Drug Administration announced it will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This complies with an ...
Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. has been hit with a prospective class action lawsuit that alleges its Combivent asthma inhaler provides far less than the number of ...
Four U.S. senators, led by Bernie Sanders, I-Vt., have sent letters to the four largest inhaler manufacturers – AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Teva Pharmaceuticals – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback